GlassScriptPhysician profile
Vasu Saini
NPI 1487048864
$69,821.05
in general payments reported to CMS, 2019-2025
22 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.05 · 2020: $331 · 2021: $4,182 · 2022: $11K · 2023: $11K · 2024: $17K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Consulting Fee: $18K · Travel and Lodging: $9,733 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,182.87 |
| Consulting Fee | $17,588.57 |
| Travel and Lodging | $9,732.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $25,307.06 | 2021-2025 | Benchmark, Penumbra System, Indigo System |
| Microvention, INC. | $14,889.71 | 2022-2025 | Sofia Ex 5f - 105cm Str, Sofia 6f-131cm Str, Web Aneurysm Embolization System |
| Stryker Corporation | $13,878.78 | 2022-2025 | Evolve, Evolve Triad, Evolve Proline |
| Balt USA, LLC | $3,836.30 | 2024-2025 | Optima Coil System, Prestige Coil System |
| Medtronic, INC. | $3,711.18 | 2021-2025 | Pipeline, Solitaire X, Osteocool Rf Ablation System |
| Medical Device Business Services, INC. | $3,212.00 | 2022-2024 | Emboguard |
| Scientia Vascular | $1,379.21 | 2023-2025 | Socrates 38 |
| Qapel Medical INC | $716.65 | 2022-2025 | |
| Depuy Synthes Sales INC. | $667.07 | 2022-2025 | Agility, Embotrap, Cerenovus Enterprise |
| Vasorum USA INC. | $638.59 | 2024 | Celt Acd |
| Imperative Care, INC | $487.67 | 2022-2025 | Zoom 88-T Large Distal Platform, Zoom Rdl Radial Access System, 103cm |
| Route 92 Medical, INC. | $237.57 | 2022 | |
| Medtronic USA, INC. | $186.84 | 2020 | |
| Chiesi USA, INC. | $168.69 | 2023-2024 | Cleviprex, Kengreal |
| Rapid Medical LTD | $161.41 | 2025 | Comaneci 17, Tigertriever 17 Revascularization Device |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $113.76 | 2025 | Lava Les (Liquid Embolic System) |
| Medtronic Vascular, INC. | $108.51 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.69 | 2019-2020 | |
| Surmodics, INC. | $25.13 | 2022 | |
| Becton, Dickinson and Company | $21.78 | 2024 | Denali Vena Cava Filter |
| Amgen INC. | $20.13 | 2020 | |
| Theragen, INC. | $13.32 | 2024 | Actastim-S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasu Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.